- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | AbbVie's Skyrizi proves a worthy Humira successor with nearly matching sales ahead of potential UC nod | ||
| Fr | Gilead writes $2.4B off Trodelvy as CEO underscores 'time of focused execution' | ||
| Fr | AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial-again | ||
| Fr | Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose | ||
| Fr | GSK pulls Pfizer and BioNTech into another vaccine patent lawsuit, this time surrounding the partners' mRNA-based COVID shots | ||
| Fr | Medtronic backs push to activate heart valve disease patients as TAVR marketing heats up | ||
| Fr | Takeda ditches industry trade group BIO following exits by WuXi AppTec, Pfizer and UCB | ||
| Fr | Fierce Pharma Asia-Novartis reworks China ties; Neurocrine-Takeda med passes depression test; Enhertu nears key readout | ||
| Do | Bristol Myers Squibb leans on long-term growth drivers, strategy overhaul to dodge IRA impacts | ||
| Do | Novo Nordisk lands back in Sanders' crosshairs, this time over steep costs of Ozempic and Wegovy | ||
| Do | Sanofi leans on COPD as 'next major growth pillar' for its immunology star Dupixent: CEO | ||
| Do | Neurocrine spotlights challenges of congenital adrenal hyperplasia patients with 'What the C@H?!' campaign | ||
| Do | AstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand, cell therapy | ||
| Do | Merck CEO Davis dubs Keytruda market exclusivity loss as 'more of a hill than a cliff' | ||
| Do | Biogen plots 30% Leqembi field force bump, omnichannel campaigns as launch enters new phase | ||
| Mi | Roche's Vabysmo shows no sign of slowdown after Regeneron and Bayer's launch of Eylea HD | ||
| Mi | Biogen 'turning the corner' as Leqembi and Skyclarys launches advance, but much work remains to be done: CEO | ||
| Mi | Chiesi survey shows how Fabry drugs are failing patients, providing road map for ousting incumbents | ||
| Mi | AbbVie starts open casting call for next faces of Botox ads, doubling down on pitch to everyday users | ||
| Mi | AstraZeneca and Merck's Lynparza set to 'dominate' PARP market as it looks to grow cancer offerings with 100-plus ongoing trials | ||
| Mi | Orphan drug market to reach $270B by 2028, led by J&J, Vertex and Roche: Evaluate | ||
| Mi | Day One takes on Novartis with FDA nod for Ojemda in broader common childhood brain tumor use | ||
| Di | Novartis dials up 2024 sales outlook, preps for key expansions of 3 cancer drugs | ||
| Di | Eli Lilly inks deal to acquire Nexus manufacturing plant in WI as Mounjaro and Zepbound shortages drag on | ||
| Di | New kid on The Bloc: Ogilvy, McCann alum Basque joins as associate creative director |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
